98%
921
2 minutes
20
Multiple components of traditional Chinese medicine (TCM) formulae determine their treatment targets for multiple diseases as opposed to a particular disease. However, discovering the unexplored therapeutic potential of a TCM formula remains challenging and costly. Inspired by the drug repositioning methodology, we propose an integrated strategy to feasibly identify new therapeutic uses for a formula composed of six herbs, Liuweiwuling. First, we developed a comprehensive systems approach to enrich drug compound-liver disease networks to analyse the major predicted diseases of Liuweiwuling and discover its potential effect on liver failure. The underlying mechanisms were subsequently predicted to mainly attribute to a blockade of hepatocyte apoptosis via a synergistic combination of multiple effects. Next, a classical pharmacology experiment was designed to validate the effects of Liuweiwuling on different models of fulminant liver failure induced by D-galactosamine/lipopolysaccharide (GalN/LPS) or thioacetamide (TAA). The results indicated that pretreatment with Liuweiwuling restored liver function and reduced lethality induced by GalN/LPS or TAA in a dose-dependent manner, which was partially attributable to the abrogation of hepatocyte apoptosis by multiple synergistic effects. In summary, the integrated strategy discussed in this paper may provide a new approach for the more efficient discovery of new therapeutic uses for TCM formulae.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884779 | PMC |
http://dx.doi.org/10.1038/s41598-018-21515-6 | DOI Listing |
Metab Brain Dis
September 2025
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Acute or chronic liver damage can result in Hepatic Encephalopathy (HE), a potentially fatal neuropsychiatric condition that leads to cerebral and neurological alterations. Dapagliflozin (DAPA), an orally active Sodium/Glucose cotransporter 2 inhibitor with long duration of action. The study aim was to evaluate the potential protective impact of DAPA against HE caused by Thioacetamide (TAA) in rats.
View Article and Find Full Text PDFLiver Int
October 2025
Department of Critical Care Medicine and Division of Gastroenterology (Liver Unit), School of Health Sciences, University of Alberta, Edmonton, Canada.
ACG Case Rep J
September 2025
Department of Medicine, University of Arizona College of Medicine, Tucson, AZ.
Hepatic hydrothorax (HH) occurs in 4%-12% of patients with cirrhosis and rarely presents without accompanying evidence of clinically significant portal hypertension (CSPH). We report the case of a 65-year-old man with cirrhosis without prior decompensation, congestive heart failure, and recurrent right-sided pleural effusion. CSPH was not otherwise observed despite thorough laboratory, radiologic, and endoscopic evaluation.
View Article and Find Full Text PDFFront Oncol
August 2025
Hunan Cancer Hospital, The Affiliated Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Tislelizumab, an anti-PD-1 monoclonal antibody, is associated with immune-related hepatitis in 1.8% of cases, but reports of acute liver failure (ALF) remain exceedingly rare. We present a case of fulminant hepatitis and ALF following Tislelizumab therapy in a 55-year-old woman with locally advanced cervical adenocarcinoma.
View Article and Find Full Text PDFCase Rep Psychiatry
August 2025
Department of Psychiatry and Behavioral Medicine, Marshall University Joan C. Edwards School of Medicine, Huntington, West Virginia, USA.
Delayed posthypoxic leukoencephalopathy (DPHL) is a rare diagnosis that may present similarly to other more common neurological conditions, such as catatonia. While often seen with carbon-monoxide poisoning, it can also be due to anoxia due to other causes, such as drug overdose or cardiac arrest. Due to the delayed nature of its symptoms and overlap with other conditions, it can be initially misdiagnosed.
View Article and Find Full Text PDF